Pneumagen
Revolutionising the management of viral respiratory tract infections
Work With Pneumagen
Innovating Antiviral Solutions for Respiratory Infections
Pneumagen is a clinical-stage biotech company developing Neumifil, a broad-spectrum antiviral, as an intranasal drug for the prophylaxis of a wide range of viral respiratory tract infections (RTIs).
The business was established in 2016 as a spin-out from the University of St Andrews in Scotland, providing access to world-class scientific expertise and capabilities in viral RTI’s specifically related to glycobiology.
Pneumagen Core Values
- Enthusiastic - displays interest and passion in a subject or an activity, with an intrinsic motivation to get involved.
- Truth-Seeking – do not accept everything at face value, instead look for evidence and validate facts before acting.
- Adaptable / problem solving - be open to challenging established views and act upon new evidence as it is presented.
- Collaborative – instinctively seeks to work with others to enable excellent outcomes.
- Engaging - naturally talk about challenges as they arise and participate without necessarily needing encouragement.
- Goal orientated - be focused and orientate energies towards completing a goal. Completes actions on time.
- Hardworking - actively engaged, keen to learn and always looking for new ways to develop with the company.
Working For Pneumagen
Pneumagen is a rapidly advancing and ambitious life sciences company. By joining their team, your work will directly support critical research by transforming the prevention and treatment of viral respiratory infections, greatly improving the lives of at-risk patients.
You'll have the opportunity to work with an experienced Management team, a world-class Scientific Advisory Board and a Clinical Advisory Group with extensive infectious disease and respiratory expertise.
The Future at Pneumagen
Pneumagen is entering an exciting phase of development, with further clinical trials planned in the coming months.
New preclinical data shows that Neumifil effectively targets multiple respiratory viruses, including influenza and coronaviruses. The findings encourage clinical trials, especially for vulnerable groups, to combat recurring and emerging respiratory infections.
